Enhancing Fluoride Mediated Dentine Sensitivity Relief through Functionalised Tricalcium Phosphate Activity

Table 2

Summary of changes in pain score (NRS-11) from baseline within each test group.

	6-week score (Tx cessation)		10-week score (4 weeks after Tx cessation)
	Pain score adjusted means	% reduction from baseline	Pain score adjusted means	% reduction from baseline
Group A
Evaporative	3.82	12%	3.50	19%
Tactile	1.60	26%	2.14	−6.10%
Hypertonic	1.42	33%	1.22	42%
CMS	2.26	20%	2.30	18%
Group B
Evaporative	3.51	19%	2.97	31%
Tactile	1.22	40%	1.27	37%
Hypertonic	1.24	41%	0.92	56%
CMS	1.97	30%	1.69	40%
Group C
Evaporative	2.39	45%	2.89	33%
Tactile	1.11	32%	1.74	14%
Hypertonic	1.26	40%	1.65	22%
CMS	1.65	42%	2.14	24%
Group D
Evaporative	2.48	43%	2.46	43%
Tactile	0.77	62%	0.72	64%
Hypertonic	0.83	61%	0.73	66%
CMS	1.35	52%	1.29	54%

Group A: Colgate Cavity Protection; Group B: Sensodyne Total Care; Group C: Clinpro Tooth Crème (brushing only); Group D: Clinpro Tooth Crème (brushing and topical application). A positive value of percentage change indicates an improvement in sensitivity at the time of assessment compared to baseline.
CMS: combined modalities score is the average of all testing modalities, evaporative, tactile, and hypertonic.
Adjusted baseline means from ANCOVA: evaporative = 4.35; tactile = 2.00; hypertonic = 2.12; CMS = 2.83.